All Products

Featured Products

Newest Products

Research Areas

IBMX
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561233

CAS#: 28822-58-4

Description: IBMX is a competitive nonselective phosphodiesterase inhibitor. IBMX raises intracellular cAMP, activates PKA, inhibits TNFα and leukotriene synthesis, and reduces inflammation and innate immunity. IBMX is also a nonselective adenosine receptor antagonist.


Price and Availability

Size Price Shipping out time Quantity
100mg USD 190 2 Weeks
250mg USD 310 2 Weeks
1g USD 610 2 Weeks
Inquire bulk and customized quantity
Pricing updated 2021-01-21. Prices are subject to change without notice.

IBMX, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561233
Name: IBMX
CAS#: 28822-58-4
Chemical Formula: C10H14N4O2
Exact Mass: 222.1117
Molecular Weight: 222.25
Elemental Analysis: C, 54.04; H, 6.35; N, 25.21; O, 14.40


Synonym: IBMX

IUPAC/Chemical Name: 3-Isobutyl-1-methylxanthine

InChi Key: APIXJSLKIYYUKG-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)

SMILES Code: O=C(N1C)N(CC(C)C)C2=C(NC=N2)C1=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Yoshimura K, Tada H, Anzai C. [Cystic fibrosis]. Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):606-11. Review. Japanese. PubMed PMID: 9645146.

2: Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002 Jul-Aug;56(6):453-9. Review. PubMed PMID: 12166544.

3: Manganiello VC, Smith CJ, Newman AH, Rice K, Degerman E, Belfrage P. Hormonal regulation of adipocyte particulate "low Km" cAMP phosphodiesterase. J Cyclic Nucleotide Protein Phosphor Res. 1986-1987;11(7):497-511. Review. PubMed PMID: 2450112.

4: Ashcroft SJ, Sugden MC, Williams IH. Carbohydrate metabolism and the glucoreceptor mechanism. Horm Metab Res Suppl. 1980;Suppl 10:1-7. Review. PubMed PMID: 6161068.

5: Bruns RF, Katims JJ, Annau Z, Snyder SH, Daly JW. Adenosine receptor interactions and anxiolytics. Neuropharmacology. 1983 Dec;22(12B):1523-9. Review. PubMed PMID: 6199685.

6: Howell SL, Tyhurst M. Insulin secretion: the effector system. Experientia. 1984 Oct 15;40(10):1098-105. Review. PubMed PMID: 6208051.

7: O'Shea Alvarez MS. 3T3 cells in adipocytic conversion. Arch Invest Med (Mex). 1991 Apr-Jun;22(2):235-44. Review. PubMed PMID: 1726451.

8: Muravyov A, Tikhomirova I. Role Ca(2+) in mechanisms of the red blood cells microrheological changes. Adv Exp Med Biol. 2012;740:1017-38. doi: 10.1007/978-94-007-2888-2_47. Review. PubMed PMID: 22453982.

9: Fredholm BB. Gastrointestinal and metabolic effects of methylxanthines. Prog Clin Biol Res. 1984;158:331-54. Review. PubMed PMID: 6084844.

10: Weir GC, Leahy JL, Bonner-Weir S. Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev. 1986;2(1-2):125-61. Review. PubMed PMID: 2424696.

11: Zufall F. Cyclic AMP-gated cation channels of olfactory receptor neurons. EXS. 1993;66:135-45. Review. PubMed PMID: 7505646.

12: Rosen OM, Smith CJ, Hirsch A, Lai E, Rubin CS. Recent studies of the 3T3-L1 adipocyte-like cell line. Recent Prog Horm Res. 1979;35:477-99. Review. PubMed PMID: 92801.

13: Niemeyer G. Retinal pharmacology in the perfused cat eye. Doc Ophthalmol. 1988 Mar-Apr;68(3-4):327-35. Review. PubMed PMID: 2456907.

14: Gilbard JP. The tear film: pharmacological approaches and effects. Adv Exp Med Biol. 1994;350:377-84. Review. PubMed PMID: 7518184.

15: Arimura A, Culler MD, Matsumoto K, Kanda M, Itoh Z, Murphy W, Shively JE, Palkovits M. Growth hormone releasing factors in the brain and the gut: chemistry, actions, and localization. Peptides. 1984;5 Suppl 1:41-4. Review. PubMed PMID: 6207512.

16: Hill HZ, Li W, Xin P, Mitchell DL. Melanin: a two edged sword? Pigment Cell Res. 1997 Jun;10(3):158-61. Review. PubMed PMID: 9266603.

17: Pekala PH, Moss J. 3T3-L1 preadipocyte differentiation and poly(ADP-ribose) synthetase. Mol Cell Biochem. 1983;53-54(1-2):221-32. Review. PubMed PMID: 6194420.

18: Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011 Dec;11(6):670-5. doi: 10.1016/j.coph.2011.09.003. Epub 2011 Sep 29. Review. PubMed PMID: 21962440; PubMed Central PMCID: PMC4034742.

19: Newby AC, Assender JW, Evans MA, Lim K, Bennett MR, Evan GI. Transduction pathways for growth stimulatory and inhibitory actions of vasoactive agents. Exp Nephrol. 1994 Mar-Apr;2(2):94-100. Review. PubMed PMID: 7521776.

20: Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J. Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann N Y Acad Sci. 1993 May 31;680:290-301. Review. PubMed PMID: 7685575.